Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis

BackgroundCheckpoint inhibitor–related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined.MethodsWe conducted a multicenter retrospective analysis of 56 patie...

Full description

Bibliographic Details
Main Authors: Chengzhi Zhou, Yilin Yang, Xinqing Lin, Nianxin Fang, Likun Chen, Juhong Jiang, Haiyi Deng, Yu Deng, Minghui Wan, Guihuan Qiu, Ni Sun, Di Wu, Xiang Long, Changhao Zhong, Xiaohong Xie, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Francesco Petrella, Alfonso Fiorelli, Sara Bravaccini, Yuki Kataoka, Satoshi Watanabe, Taichiro Goto, Piergiorgio Solli, Hitoshi Igai, Yuichi Saito, Nikolaos Tsoukalas, Takeo Nakada, Shiyue Li, Rongchang Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
immune checkpoint inhibitor
checkpoint inhibitor-related pneumonitis
clinical phases
management
glucocorticoids
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.935779/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.935779/full

Similar Items